Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Coherus Biosciences ( (CHRS) ).
On February 12, 2026, Coherus Oncology, Inc. entered into an underwriting agreement with a syndicate of underwriters to sell 28,600,000 shares of its common stock at a public price of $1.75 per share, with an additional 4,290,000-share over-allotment option available for the underwriters. The offering was conducted under an effective shelf registration statement, included customary representations and indemnification provisions, and imposed a 60-day lock-up on sales of company stock by the issuer, its directors, executive officers and certain affiliated stockholders.
On February 17, 2026, the company completed the sale and issuance of the 28,600,000 shares of common stock, generating net proceeds of approximately $47.0 million after underwriting discounts and commissions but before offering expenses. The capital raise strengthens Coherus Oncology’s balance sheet and provides additional financial resources that can be used to support its oncology portfolio and ongoing operations, while the lock-up arrangements help stabilize the company’s share trading in the near term.
The most recent analyst rating on (CHRS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Coherus Biosciences stock, see the CHRS Stock Forecast page.
Spark’s Take on CHRS Stock
According to Spark, TipRanks’ AI Analyst, CHRS is a Neutral.
The score is held down primarily by weak financial performance (revenue contraction, negative operating metrics, and ongoing cash burn). Offsetting factors include supportive technical momentum and a positive earnings-call narrative around LOQTORZI growth, expense control, and liquidity, with incremental upside from the Janssen collaboration.
To see Spark’s full report on CHRS stock, click here.
More about Coherus Biosciences
Coherus Oncology, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of oncology therapies. The company accesses capital markets to support its drug development programs and related operational needs, positioning itself as a growth-stage player within the competitive cancer treatment sector.
Average Trading Volume: 2,001,597
Technical Sentiment Signal: Hold
Current Market Cap: $194.6M
See more insights into CHRS stock on TipRanks’ Stock Analysis page.